The company has built a vertically integrated, GMP-compliant pharmaceutical platform through a strategic investment in PsyLabs. Psyence expanded its Australian clinical site network from three to five sites in April 2026, supporting multi-site Phase IIb trials of pharmaceutical-grade psilocybin for Adjustment Disorder in palliative oncology.
Cyborg Score Rationale
The company has a market cap of approximately $15.3 million as of May 2026, indicating a micro-cap status. The balance sheet shows strong cash position (~$6.2M) against minimal liabilities (~$0.6M), but the EPS (TTM) is significantly negative at -34.78. Clinical-stage development and recent shareholder litigation create execution risk.
Top Insights
Positioned at forefront of psychedelic therapy commercialization with Nasdaq listing and regulatory focus on ibogaine safety evaluation (April 2026)
Experienced severe stock volatility following ibogaine policy catalyst in April 2026, surging 44.8% week-over-week before settling
Underwent consecutive share consolidations (1-for-7.97 in May 2025 and 1-for-6.25 in February 2026) indicating stock pressure and dilution management challenges
Strategic equity investment in PsyLabs supplier positions company for vertical integration but results in significant shareholder dilution (~50% ownership to supplier)
Named Competitors
COMPASS Pathways — COMPASS Therapeutics: Psilocybin-based therapies for treatment-resistant depression
Tryp Therapeutics — Psilocybin development for mental health disorders
Ketamine — FDA-approved ketamine nasal spray (Spravato) for depression
Recent Developments
(February 2026) Announced settlement of shareholder litigation with KAOS Capital Ltd regarding alleged oppressive actions
(February 2026) Completed 1-for-6.25 reverse stock split effective February 2, 2026; shareholders approved authority for future consolidations up to 250:1
(April 2026) Expanded Australian clinical trial sites from three to five sites; stock surged 44.8% following U.S. executive action preparation announcement regarding ibogaine evaluation
(February 2026) PsyLabs exercised put option triggering $5M equity investment; PBM issued 1,146,159 shares, leaving PsyLabs with ~49.98% ownership
Open the full interactive Psyence Biomedical Ltd. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.